These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 31754882)

  • 21. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
    Hosoya T; Sasaki T; Ohashi T
    Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males.
    Furihata K; Nagasawa K; Hagino A; Kumagai Y
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):36-43. PubMed ID: 32076889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
    Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
    Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
    [No Abstract]   [Full Text] [Related]  

  • 25. Unique Binding Sites of Uricosuric Agent Dotinurad for Selective Inhibition of Renal Uric Acid Reabsorptive Transporter URAT1.
    Fujita K; Isozumi N; Zhu Q; Matsubayashi M; Taniguchi T; Arakawa H; Shirasaka Y; Mori E; Tamai I
    J Pharmacol Exp Ther; 2024 Jun; 390(1):99-107. PubMed ID: 38670801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in Urinary Uric Acid Concentration after Dotinurad Administration to Patients with Hyperuricemia: A Post Hoc Analysis of Two Clinical Trials in Japan.
    Takahashi T; Sasaki M; Shimizu T; Yamaguchi S
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):87-95. PubMed ID: 37559414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Cells; 2024 Mar; 13(5):. PubMed ID: 38474414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacological properties and clinical efficacy of dotinurad (URECE
    Taniguchi T; Ashizawa N
    Nihon Yakurigaku Zasshi; 2020; 155(6):426-434. PubMed ID: 33132262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
    Tan PK; Liu S; Gunic E; Miner JN
    Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
    Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
    Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
    J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications.
    Song D; Zhao X; Wang F; Wang G
    Eur J Pharmacol; 2021 Sep; 907():174291. PubMed ID: 34216576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
    Lee HA; Yu KS; Park SI; Yoon S; Onohara M; Ahn Y; Lee H
    Rheumatology (Oxford); 2019 Nov; 58(11):1976-1984. PubMed ID: 31056705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study.
    Lin Y; Chen X; Ding H; Ye P; Gu J; Wang X; Jiang Z; Li D; Wang Z; Long W; Li Z; Jiang G; Li X; Bi L; Jiang L; Wu J; Guo L; Cai X; Lu X; Chen Q; Chen H; Peng A; Zuo X; Ning R; Zhang Z; Tai Y; Zhang T; Bao C
    Rheumatology (Oxford); 2021 Nov; 60(11):5089-5097. PubMed ID: 33693494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.
    Terkeltaub R; Lee J; Min J; Shin S; Saag KG
    Arthritis Rheumatol; 2023 Jul; 75(7):1275-1284. PubMed ID: 36649008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.
    Nakatani H; Fushimi M; Sasaki T; Okui D; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):8-16. PubMed ID: 31889230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
    Hosoya T; Ohno I; Nomura S; Hisatome I; Uchida S; Fujimori S; Yamamoto T; Hara S
    Clin Exp Nephrol; 2014 Dec; 18(6):876-84. PubMed ID: 24448692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.